This website uses cookies. For more information please contact us or consult our privacy policy.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Norman Greenberg
Norman E. Greenberg
Associate
New York +1 212 841 1193 ngreenberg@cov.com Download V-card

Norman Greenberg represents clients in a broad range of corporate transactions. His practice primarily covers mergers and acquisitions, corporate governance and general corporate matters.

  • AbbVie Inc. in its $5.8 billion acquisition of Stemcentrx and its novel rovalpituzumab (Rova-T) compound for small cell lung cancer.
  • Tencent in its $8.6 billion acquisition of a majority interest in Supercell.
  • Allergan in its $2.1 billion acquisition of publicly traded KYTHERA Biopharmaceuticals, Inc.
  • Ben Silverman in the establishment of Propagate Content, a media production and distribution company, with funding from A+E Network
  • Fund of funds in numerous private equity fund secondary transactions.
  • Pharming Group N.V. in its $125 million acquisition of all North American commercialization rights to Ruconest® from Valeant.
  • Allergan plc in its acquisition of Oculeve, Inc.
  • ITOCHU Corporation and ITOCHU International in the sale of PrimeSource Building Products, a North American distributor of building materials, to an affiliate of Platinum Equity.
  • Advised clients on corporate and governance related matters, including compliance and disclosure issues, board charters and policies, and defense and takeover measures.

Pro Bono

  • Advised non-profit clients in connection with significant life cycle events, and provided governance and other advice to non-profit boards.
  • Assisted non-profit organizations with federal tax exemption.